Abrupt onset of type 1 diabetes mellitus during recombinant interferon-alpha 2b therapy in a patient with chronic hepatitis B

Lv, Yuanyuan; Shi, Bingyin; Hui, Guo

doi:10.3748/wjg.14.4713

Cited by 7 publications

(4 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, the use of interferon can have a strong anti-hepatitis B virus effect on patients with hepatitis B cirrhosis, to better improve the clinical symptoms of patients and the development of liver cirrhosis, which is of great significance [ 36 ]. In particular, the 2015 APASL guidelines recommend that interferon can be used for initial antiviral therapy in patients with pre-cirrhosis and interferon in compensatory cirrhosis [ 37 ]. The reasons are as follows: (1) interferon therapy can prevent the progression of liver cirrhosis; (2) interferon therapy can stop medication within a limited course of treatment; and (3) interferon therapy can improve the response rate of interferon.…”

Section: Discussionmentioning

confidence: 99%

“…erefore, the use of interferon can have a strong anti-hepatitis B virus effect on patients with hepatitis B cirrhosis, to better improve the clinical symptoms of patients and the development of liver cirrhosis, which is of great significance [36]. In particular, the 2015 APASL guidelines recommend that interferon can be used for initial antiviral therapy in patients with pre-cirrhosis and interferon in compensatory cirrhosis [37].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Effects of Tenofovir Combined with Recombinant Human Interferon α-2b on Negative Conversion Rate, Liver Function, Immune Status, and Drug Safety in Patients with Chronic Hepatitis B: A Systematic Review and Meta-Analysis

Hui

Xian

Yang

et al. 2022

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

Objective. To systematically evaluate the clinical value of tenofovir combined with recombinant human interferon α-2b in the treatment of chronic hepatitis B and to provide evidence-based medicine for its popularization and use. Methods. The randomized controlled trials (RCTs) of tenofovir combined with recombinant human interferon α-2b in the online database of PubMed, EMBASE, ScienceDirect, Cochrane Library, China knowledge Network (CNKI), China VIP database, Wanfang database, and China Biomedical Literature Database (CBM) were searched. The data included in this study were extracted by two independent researchers. After extracting the data of the study, the Cochrane manual 5.1.0 standard was used to evaluate the bias risk of all the literature included in this study. RevMan5.4 statistical software was used to analyze the collected data by meta. Results. Entecavir combined with recombinant human interferon α-2b can inhibit the activity of HBV polymerase and improve the inflammatory response of the liver. Recombinant human interferon α-2b can regulate immune function by inducing T cell differentiation and maturation and enhancing the production of cytokines. The systematic evaluation showed that entecavir combined with recombinant human interferon α-2b had higher serum HBeAg negative conversion rate, higher drug safety compared with entecavir alone, and improved liver function and immune status. Conclusion. Tenofovir combined with recombinant human interferon alpha-2b has a high serum HBeAg negative rate and safety profile for the treatment of chronic hepatitis B. The combination treatment can improve liver function and immune status in patients, but more studies with higher methodological quality and longer duration of intervention are needed for further validation.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Effects of Tenofovir Combined with Recombinant Human Interferon α-2b on Negative Conversion Rate, Liver Function, Immune Status, and Drug Safety in Patients with Chronic Hepatitis B: A Systematic Review and Meta-Analysis

Hui

Xian

Yang

et al. 2022

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

show abstract

“…Patients were evaluated for clinical characteristics such as age, sex, IFN type, ribavirin use, treatment duration of IFN before the onset of diabetes, HLA type, and glutamate decarboxylase antibody-positive rate. We retrieved 82 cases of IFN-associated diabetes, including 1 case of our own (Supplementary Material 2) 4 5 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 . According to the consensus report by the ADA and the EASD 57 , we identified all IFN-associated type 1 diabetes cases.…”

Section: Methodsmentioning

confidence: 99%

Characteristics of Interferon-Associated Diabetes Mellitus in Past 30 Years: A Review

et al. 2022

View full text Add to dashboard Cite

Interferon (IFN) is a broad-spectrum antiviral agent that activates cell surface receptors and causes cells to produce antiviral proteins, inhibiting viral replication. Interferon use has long been associated with diabetes. The PubMed database was searched for articles related to diabetes and interferon from March 30, 2020. Patients were divided into type 1 diabetes group and type 2 diabetes group. We reviewed the relevant literature to compare interferon-associated T1D and interferon-associated T2D differences. Interferon treatment shortened the incubation period of T2D and changed the original T2D to T1D. The onset of interferon-associated T1D required longer periods of IFN treatment than interferon-associated T2D, and the interferon-associated T1D group had higher GADA positive rates, lower BMI, lower fasting blood glucose, and greater insulin dependence (p<0.05). More patients in the T1D group were positive for HLA-DRB1*04, DRB1*03, DRB1*09, DRB1*14, HLA-DQB1*04, HLA-DQB1*02, HLA-DQB1*03, and HLA-DQB1*05. The combined detection of GAD antibodies and HLA alleles may be an effective method to predict the incidence of T1D after IFN treatment.

show abstract

“…Hepatitis B virus (HBV) is a public health problem worldwide with approximately two billion people infected; about 400 million persons are chronic carriers globally [1]. Interferon-alpha is widely used in the treatment of chronic hepatitis B and C [2]. Interferons (IFNs) are polypeptides produced by eucaryotic cells which are composed of three families containing type I IFNs (mainly IFNalpha, IFN-beta), type II IFN (IFN-gamma), and type III IFNs.…”

Section: Introductionmentioning

confidence: 99%

Chronic hepatitis b with type I diabetes mellitus and autoimmune thyroiditis development during interferon alpha therapy

Köse

Gozaydin

Akkoçlu

et al. 2011

J Infect Dev Ctries

View full text Add to dashboard Cite

Interferon alpha is a molecule frequently used in the treatment of chronic hepatitis B, C, and D, with immunomodulatory and antiviral activity. It is also used in some cancer types. It has been widely claimed that interferon alpha triggers autoimmunity, with its broad adverse effect profile. Here we present the case of a 29-year-old male patient with chronic hepatitis B diagnosis who developed type 1 diabetes mellitus and autoimmune thyroiditis during treatment with interferon alfa-2b. Within four months of initiation of treatment with interferon alfa-2b, the patient presented to our clinic with dry mouth, urinary frequency (8 to 10 times per day), drinking plenty of water, night time urination, and tiredness. He was admitted to the clinic when his fasting blood glucose level was detected to be high. After examinations, the patient was diagnosed with type 1 diabetes and autoimmune thyroiditis and began to receive treatment with insulin and propranolol. Fasting blood glucose levels were controlled and thyroid hormones decreased to normal levels within one month after the treatments began. For patients who will receive treatment with interferon alpha, especially those individuals with chronic hepatitis, pancreatic autoantibodies should be checked and close monitoring should be performed as there may be glucose tolerance impairment in patients with high titers. In addition, follow-up with thyroid function tests should be performed prior to and during the treatment.

show abstract

Abrupt onset of type 1 diabetes mellitus during recombinant interferon-alpha 2b therapy in a patient with chronic hepatitis B

Abstract: Lv YY, Shi BY, Guo H. Abrupt onset of type 1 diabetes mellitus during recombinant interferon-alpha 2b therapy in a patient with chronic hepatitis B.

Cited by 7 publications

References 15 publications

Effects of Tenofovir Combined with Recombinant Human Interferon α-2b on Negative Conversion Rate, Liver Function, Immune Status, and Drug Safety in Patients with Chronic Hepatitis B: A Systematic Review and Meta-Analysis

Effects of Tenofovir Combined with Recombinant Human Interferon α-2b on Negative Conversion Rate, Liver Function, Immune Status, and Drug Safety in Patients with Chronic Hepatitis B: A Systematic Review and Meta-Analysis

Characteristics of Interferon-Associated Diabetes Mellitus in Past 30 Years: A Review

Chronic hepatitis b with type I diabetes mellitus and autoimmune thyroiditis development during interferon alpha therapy

Contact Info

Product

Resources

About